NASDAQ:COLL Collegium Pharmaceutical (COLL) Stock Price, News & Analysis $29.90 +0.11 (+0.37%) Closing price 04:00 PM EasternExtended Trading$29.88 -0.01 (-0.05%) As of 06:07 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About Collegium Pharmaceutical Stock (NASDAQ:COLL) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get COLL alerts:Sign Up Key Stats Today's Range$29.45▼$30.0850-Day Range$25.99▼$30.4452-Week Range$23.23▼$42.29Volume200,821 shsAverage Volume401,375 shsMarket Capitalization$960.69 millionP/E Ratio24.51Dividend YieldN/APrice Target$43.75Consensus RatingModerate Buy Company OverviewCollegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.Read More… Collegium Pharmaceutical Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks69th Percentile Overall ScoreCOLL MarketRank™: Collegium Pharmaceutical scored higher than 69% of companies evaluated by MarketBeat, and ranked 298th out of 935 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.4 / 5Analyst RatingModerate Buy Consensus RatingCollegium Pharmaceutical has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageCollegium Pharmaceutical has only been the subject of 2 research reports in the past 90 days.Read more about Collegium Pharmaceutical's stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings Growth7.12% Earnings GrowthEarnings for Collegium Pharmaceutical are expected to grow by 7.12% in the coming year, from $5.62 to $6.02 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Collegium Pharmaceutical is 24.51, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 24.01.Price to Earnings Ratio vs. SectorThe P/E ratio of Collegium Pharmaceutical is 24.51, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 18.27.Price to Book Value per Share RatioCollegium Pharmaceutical has a P/B Ratio of 4.21. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Collegium Pharmaceutical's valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted15.91% of the float of Collegium Pharmaceutical has been sold short.Short Interest Ratio / Days to CoverCollegium Pharmaceutical has a short interest ratio ("days to cover") of 13.4, which indicates bearish sentiment.Change versus previous monthShort interest in Collegium Pharmaceutical has recently decreased by 3.54%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCollegium Pharmaceutical does not currently pay a dividend.Dividend GrowthCollegium Pharmaceutical does not have a long track record of dividend growth. Sustainability and ESG3.0 / 5Environmental Score-2.78 Percentage of Shares Shorted15.91% of the float of Collegium Pharmaceutical has been sold short.Short Interest Ratio / Days to CoverCollegium Pharmaceutical has a short interest ratio ("days to cover") of 13.4, which indicates bearish sentiment.Change versus previous monthShort interest in Collegium Pharmaceutical has recently decreased by 3.54%, indicating that investor sentiment is improving. News and Social Media1.5 / 5News Sentiment0.63 News SentimentCollegium Pharmaceutical has a news sentiment score of 0.63. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.98 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Collegium Pharmaceutical this week, compared to 5 articles on an average week.Search InterestOnly 2 people have searched for COLL on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Collegium Pharmaceutical to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership0.8 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Collegium Pharmaceutical insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $202,123.00 in company stock.Percentage Held by InsidersOnly 2.51% of the stock of Collegium Pharmaceutical is held by insiders.Read more about Collegium Pharmaceutical's insider trading history. Receive COLL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Collegium Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter. Email Address COLL Stock News HeadlinesCollegium Pharmaceutical, Inc. (NASDAQ:COLL) Director Sells $202,122.62 in StockJune 12, 2025 | insidertrades.comANI Pharmaceuticals Shows Rising Relative Price Performance; Still Shy Of Key BenchmarkJune 23 at 1:36 PM | msn.comA new rule goes live in July — and the banks are quietly cashing inA major change is quietly going into effect this July — and Wall Street is already positioning for it. Big Banks have found a way to use a new asset as if it were cash. Not stocks. Not bonds. Not even the U.S. dollar. They now trust this asset more than the traditional financial system itself.June 26 at 2:00 AM | American Alternative (Ad)Q1 Rundown: Royalty Pharma (NASDAQ:RPRX) Vs Other Branded Pharmaceuticals StocksJune 20, 2025 | msn.com1 Russell 2000 Stock on Our Watchlist and 2 to Keep Off Your RadarJune 17, 2025 | msn.comJohn G. Freund MD At Collegium Pharmaceutical Decides to Exercises Options Worth $243KJune 12, 2025 | benzinga.comCOLL Q1 Earnings Call: ADHD Portfolio Drives Growth, Management Details Capital Deployment PrioritiesJune 10, 2025 | msn.comStocks To Watch: Dr. Reddy's Labs ADR Sees Relative Strength Rating Jump To 81June 6, 2025 | msn.comSee More Headlines COLL Stock Analysis - Frequently Asked Questions How have COLL shares performed this year? Collegium Pharmaceutical's stock was trading at $28.65 at the beginning of the year. Since then, COLL stock has increased by 4.4% and is now trading at $29.90. View the best growth stocks for 2025 here. How were Collegium Pharmaceutical's earnings last quarter? Collegium Pharmaceutical, Inc. (NASDAQ:COLL) announced its earnings results on Thursday, May, 8th. The specialty pharmaceutical company reported $1.49 earnings per share for the quarter, missing analysts' consensus estimates of $1.50 by $0.01. The company's revenue for the quarter was up 22.7% compared to the same quarter last year. Read the conference call transcript. When did Collegium Pharmaceutical IPO? Collegium Pharmaceutical (COLL) raised $75 million in an IPO on Thursday, May 7th 2015. The company issued 5,800,000 shares at a price of $12.00-$14.00 per share. Jefferies and Piper Jaffray acted as the underwriters for the IPO and Wells Fargo Securities and Needham & Company were co-managers. Who are Collegium Pharmaceutical's major shareholders? Collegium Pharmaceutical's top institutional investors include Eventide Asset Management LLC (8.21%), Vanguard Group Inc. (6.99%), Invesco Ltd. (5.08%) and Principal Financial Group Inc. (4.90%). Insiders that own company stock include Joseph Ciaffoni, Colleen Tupper, Scott Dreyer, Shirley R Kuhlmann, John Gordon Freund, Thomas B Smith, Garen G Bohlin and Michael Thomas Heffernan. View institutional ownership trends. How do I buy shares of Collegium Pharmaceutical? Shares of COLL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Collegium Pharmaceutical own? Based on aggregate information from My MarketBeat watchlists, some other companies that Collegium Pharmaceutical investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Broadcom (AVGO), Arista Networks (ANET), Netflix (NFLX) and CrowdStrike (CRWD). Company Calendar Last Earnings5/08/2025Today6/26/2025Next Earnings (Estimated)8/06/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - DRUGS Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:COLL CIK1267565 Webwww.collegiumpharma.com Phone(781) 713-3699FaxN/AEmployees210Year FoundedN/APrice Target and Rating Average Stock Price Target$43.75 High Stock Price Target$50.00 Low Stock Price Target$37.00 Potential Upside/Downside+47.0%Consensus RatingModerate Buy Rating Score (0-4)2.75 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)$1.22 Trailing P/E Ratio24.39 Forward P/E Ratio5.30 P/E GrowthN/ANet Income$69.19 million Net Margins6.61% Pretax Margin9.80% Return on Equity99.08% Return on Assets15.14% Debt Debt-to-Equity Ratio3.30 Current Ratio1.08 Quick Ratio1.01 Sales & Book Value Annual Sales$631.45 million Price / Sales1.51 Cash Flow$12.20 per share Price / Cash Flow2.44 Book Value$7.10 per share Price / Book4.19Miscellaneous Outstanding Shares32,130,000Free Float31,325,000Market Cap$956.19 million OptionableOptionable Beta0.63 Social Links Options Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free Report This page (NASDAQ:COLL) was last updated on 6/26/2025 by MarketBeat.com Staff From Our PartnersThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredWhy July is critical for your stocksBig Study Shows Stocks Extremely Likely to Crash in 2026? Legendary quant analyst Marc Chaikin says in 50 y...Chaikin Analytics | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredCrypto Is Pumping Again – Now Comes the Real OpportunityThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredTrump Knows Exactly What He’s Doing…With Trump in office, new money is flowing in and out of the market like never before... And some folks usi...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Collegium Pharmaceutical, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Collegium Pharmaceutical With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.